Details for Patent: 8,722,705

Title:	Methods for treating diffuse large B-cell lymphoma with 3-(4-amino-1-OXO-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione in combination with second active agents
Abstract:	Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of an immunomodulatory compound. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.
Inventor(s):	Zeldis; Jerome B. (Princeton, NJ)
Assignee:	Celgene Corporation (Summit, NJ)
Filing Date:	Jul 15, 2013
Application Number:	13/942,232
Claims:	1. A method of treating diffuse large B-cell lymphoma, which comprises administering to a human having diffuse large B-cell lymphoma (a) from about 5 to about 50 mg per day of a compound having the formula of ##STR00009## or a pharmaceutically acceptable salt, solvate or stereoisomer thereof; (b) a therapeutically effective amount of rituximab; and (c) a therapeutically effective amount of one or more additional active agents. 2. The method of claim 1, wherein the diffuse large B-cell lymphoma is newly diagnosed. 3. The method of claim 1, wherein the diffuse large B-cell lymphoma is relapsed, refractory or resistant to conventional therapy. 4. The method of claim 1, wherein the one or more additional active agents comprise a hematopoietic growth factor, a cytokine, an anticancer agent, an antibiotic, a cox-2 inhibitor, an immunomodulatory agent, an immunosuppressive agent, a corticosteroid, or a pharmacologically active mutant or derivative thereof, or a combination thereof. 5. The method of claim 1, wherein the one or more additional active agents comprise cyclophosphamide, doxorubicin, vincristine, prednisone, or a combination thereof. 6. The method of claim 5, wherein the one or more additional active agents comprise cyclophosphamide, doxorubicin, vincristine and prednisone. 7. The method of claim 1, wherein the compound is ##STR00010## 8. The method of claim 1, wherein the compound is a pharmaceutically acceptable salt. 9. The method of claim 1, wherein the compound is a pharmaceutically acceptable solvate. 10. The method of claim 1, wherein the compound is a pharmaceutically acceptable stereoisomer. 11. The method of claim 10, wherein the stereoisomer is an enantiomerically pure R isomer or an enantiomerically pure S isomer. 12. The method of claim 1, wherein the compound is administered orally. 13. The method of claim 12, wherein the compound is administered in the form of a capsule or tablet. 14. The method of claim 1, wherein the compound is administered in an amount of about 5, 7.5, 10, 12.5, 15, 20, 25, or 50 mg per day. 15. The method of claim 14, wherein the compound is administered in an amount of about 15 mg per day. 16. The method of claim 14, wherein the compound is administered in an amount of about 7.5 mg per day. 17. The method of claim 1, wherein the compound is administered cyclically. 18. The method of claim 1, wherein the rituximab is administered in an amount of about 375 mg/m.sup.2. 19. The method of claim 1, wherein the rituximab is administered cyclically. 20. The method of claim 1, wherein the one or more additional active agents are administered cyclically. 21. The method of claim 13, wherein the capsule comprises the compound, lactose anhydrous, microcrystalline cellulose, croscarmellose sodium and magnesium stearate.